Indivior Pharmaceuticals, Inc. Common Stock (INDV) Financials
Key financial figures for Indivior Pharmaceuticals, Inc. Common Stock (Q3 2026).
Indivior Q3 2026 net revenue $356M (up 13% YoY) with record Sublocade net revenue of $267M and record net income of $137M; merger with Supernus expected to close November 2. Total net revenue was $356M, up 13% from $314M a year earlier; total SUBLOCADE net revenue was a record $267M, up 22% YoY (U.S. SUBLOCADE $252M, up 24%, on 17% dispense unit volume growth). GAAP net income was $137M ($1.12 diluted EPS) vs $42M ($0.33) a year earlier; non-GAAP diluted EPS was $1.32 vs $0.72. Adjusted EBITDA was a record $211M, up 76% YoY (59% margin, up 2,100 bps); GAAP operating expenses fell 33% to $125M. Cash and investments were $332M at quarter end. On the outlook: On track for previously communicated FY2026 standalone guidance: net revenue $1,295M to $1,365M, total SUBLOCADE net revenue $1,010M to $1,050M, non-GAAP operating expenses $430M to $450M, adjusted EBITDA $700M to $740M. The release says the guidance will no longer apply once the Supernus merger closes (expected November 2, 2026). Figures are for Q3 2026, as Indivior reported them.
- Revenue
- $356M
- Net Income
- $137M
- EPS
- $1.16
- Total Assets
- $1.3B
- Operating Cash Flow
- $97M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $356M | $137M | $1.12 | 50.84% | $83M |
| Q2 FY2026 | $343M | $122M | $0.98 | 46.65% | $222M |
| Q1 FY2026 | $317M | $89M | $0.69 | 43.22% | -$29M |
| Q4 FY2025 | $358M | $102M | $0.82 | 34.08% | -$245M |
| Q3 FY2025 | $314M | $42M | $0.33 | 31.53% | -$59M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $1.2B | $210M | $1.64 | 21.39% | -$94M |
| FY2024 | $1.2B | $2M | $0.05 | 2.69% | $5M |
| FY2023 | $1.1B | -$129M | -$0.92 | -14.27% | -$353M |
Frequently asked questions
What was Indivior's revenue last quarter?
Indivior reported revenue of $356.0 million for Q3 FY2026, up 13.4% from the same period a year earlier.
Is Indivior profitable?
Yes. Indivior reported net income of $137.0 million for Q3 FY2026, a net margin of 38.48% on revenue.
How has Indivior's margin trended?
Operating margin was 50.84% in Q3 FY2026, compared with 31.53% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Indivior generate?
Indivior generated free cash flow of $83.0 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Indivior Pharmaceuticals, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.